Clinical Trial Update: Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and immunogenicity of Ervebo and Zabdeno booster vaccines against Ebola virus in people previously vaccinated with Zabdeno/Mvabe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Ervebo (rVSVΔG-ZEBOV-GP)
• Zabdeno (Ad26.ZEBOV vaccine)

Snippet

Sponsor: Institute of Tropical Medicine, Belgium | Conditions: Ebola Virus Disease | Phase 3 | Status: RECRUITING